[Note from SaneVax: On 10 April 2011, the AAVP in Spain sent the following press release to their local newspaper. The SaneVax Team just got word today that the editor(s) obviously didn’t think the article was news-worthy and neglected to publish it. We disagree, particularly since medical authorities are using Gardasil® for older women, regardless of the most recent FDA decision not to expand its use to include women over the age of 26. Therefore, a rough English translation of the entire article appears below. Hopefully, the people of Spain can get the news here.]
The FDA has rejected the use of Gardasil for women 27 to 45 years following the request from Merck to the FDA for expanded use of Gardasil in adult population.
From AAVP (Association of Concerned by Papillomavirus Vaccine) believe that this decision is a victory for consumers around the world.
A press conference conducted by Merck on April 6, 2011 indicates that the FDA has said not enough evidence to prove that Gardasil prevents cervical cancer related to HPV in women older than 27 years.
Similarly, AAVP believes that Gardasil has not yet demonstrated its efficacy in preventing cervical cancer in women under 26 years, since they do not know the real effectiveness before 30-35 years, since cancer is intended prevent it takes 30 or more years to develop, and trials have been conducted have only been six years (phase II) and three years (phase III). Therefore, given the brevity of the tests would have to wait many years to compare the development of breast cancer in women who have been vaccinated and those who do not have. We believe that in Spain, where the incidence of this disease is very low, wait should have been more prudent.
To all this, join the notification of adverse events that are occurring worldwide. In VAERS (American System of Adverse Reactions to Vaccines) and has been reported 93 deaths and 21,292 adverse reaction reports. This fact is very significant especially if we consider that only 10% of reported cases.
AAVP asked the Spanish Agency of Medicines and Health Products (Competent Authority) a list of adverse effects on our country. Until September 15, 2009 are recorded 508 reports of suspected adverse reactions associated with vaccines against HPV, without knowing which is the data today.
What worries us is that in Europe and specifically in Spain has expanded the use of Gardasil for women up to age 45, when there are studies that confirm the drug itself, which in the case of a woman is infected by some of the virus in the vaccine, there is an increase of 44.6% in the risk of cervical cancer.
AAVP calls on the Spanish health authorities to suspend the extension of vaccination to 45 years early. It also requests the withdrawal of the vaccine market, while not an independent study on its safety and effectiveness of not doing so will risky “reckless” the health of women and the Health of this country.
Learn more at http://www.aavp.es